Open AccessMepolizumab improved airway hyperresponsiveness in a patient with allergic bronchopulmonary aspergillosis
Author(s) -
Chisato Onitsuka,
Tetsuya Homma,
Tomoko Kawahara,
Takeshi Kimura,
Yoshito Miyata,
Hironori Sagara
Publication year - 2021
Publication title -
asian pacific journal of allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 33
ISSN - 0125-877X
DOI - 10.12932/ap-030521-1125
Subject(s) - allergic bronchopulmonary aspergillosis , mepolizumab , medicine , immunology , eosinophilia , asthma , eosinophil , pathogenesis , allergy , interleukin 5 , aspergillus fumigatus , immunoglobulin e , interleukin , antibody , cytokine
Allergic bronchopulmonary aspergillosis (ABPA) is a severe type of asthma characterized by hypersensitivity to Aspergillus fumigatus and lung infiltration with eosinophilia. The central pathogenesis of asthma is airway hyperresponsiveness (AHR), with eosinophils playing a critical role. Anti-interleukin (IL)-5 antibody therapy has been recently introduced to treat severe asthma, which reportedly inactivates and reduces eosinophil count. A recent case series highlighted the improvement in asthmatic symptoms associated with ABPA, but previous reports failed to demonstrate any improvement in AHR.